clinical trial design

Now more than ever before, recruiting patients for a research study doesn’t have to mean getting them to leave their homes.

Few peer-reviewed clinical papers on the pandemic contained original data, and many of those that did had poor experimental design.

As COVID-19 therapies get emergency-use green lights, the Biden administration must organize a therapeutic review board to help identify what’s working and what’s not.

Although scientists debate the ethics of deliberately infecting volunteers with SARS-CoV-2, plenty of consenting participants have been exposed to all sorts of pathogens in prior trials.

A randomized controlled trial on the use of convalescent plasma therapy to treat coronavirus infections—the first in the world to be completed—yields disappointing results, but some doctors are not discouraged.

UPenn’s Katharine Bar discusses ongoing clinical trials to explore the efficacy of treating patients with plasma from individuals who have recovered from an infection.

Upon seeing pregnant women sick with COVID-19 at a University of Pennsylvania hospital, researchers there wrote trial protocols for blood transfusions to treat the disease that include expecting mothers.

The idea of deliberately infecting volunteers with SARS-CoV-2 has garnered significant attention as a potential avenue to speedier development, as the World Health Organization weighs in with recommendations.

Under careful watch of the World Health Organization, doctors will test a range of COVID-19 therapies, including HIV and flu antivirals, blood plasma infusions, and traditional Chinese medicines.

A technique called Mendelian randomization is overturning the conclusions of observational studies in public health. But researchers question whether the method can overcome its fundamental limitations.

A look at some of the circulating molecules that may indicate various Alzheimer’s pathologies and serve as the bases of noninvasive tests for the disease.

Researchers hope circulating biomarkers will enable earlier detection and better monitoring of the neurodegenerative disorder—and perhaps help usher in new treatments.

A new study suggests that sponsors downplay their influence when reporting trials carried out in collaboration with academic researchers.

What can be done to lower development costs and drug prices?

Thoughts on how to redesign clinical trials for traumatic brain injury

The National Cancer Institute is launching a Phase 2 trial matching patients with specific mutations to drugs tailored to those genetic changes.

Enrolling the right patient population could be key to a successful clinical trial.